Shanghai Pharmaceuticals Holding Co ( (HK:2607) ) has shared an announcement.
Shanghai Pharmaceuticals Holding Co., Ltd. announced its 2024 annual results, audited by Deloitte Touche Tohmatsu, reflecting the company’s adherence to China Accounting Standards. The results, reviewed by the Audit Committee, will be published on the Hong Kong Stock Exchange and the company’s website. This announcement underscores the company’s commitment to transparency and its strategic positioning in the pharmaceutical industry, potentially impacting stakeholders by reinforcing its market reputation.
More about Shanghai Pharmaceuticals Holding Co
Shanghai Pharmaceuticals Holding Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the pharmaceutical industry. The company focuses on manufacturing leading brand medicines and providing healthcare services, aiming to enhance people’s healthy living quality through innovation, integrity, cooperation, tolerance, and responsibility.
YTD Price Performance: -8.59%
Average Trading Volume: 33,967
Technical Sentiment Signal: Sell
Current Market Cap: $7.67B
See more data about 2607 stock on TipRanks’ Stock Analysis page.